Project Description

NECTIN THERAPEUTICS

At a glance

Established by Integra Holdings in 2017, Nectin Therapeutics is developing novel monoclonal antibodies directed towards Nectin receptors and ligands, playing major roles in immune checkpoint mechanisms relevant for cancer immune therapy.
The platform was developed by Prof. Ofer Mandelboim from the Immunology & Cancer Research Center at the Hebrew University and Prof. Stipan Jonjic from the Department of Histology and Embryology/Center for Proteomics, Faculty of Medicine, University of Rijeka.

Market Potential

The global market for Immune Oncology was estimated at $5.5 billion in 2016, with increasing market share and sales of novel immune checkpoint blockers currently developed and marketed by major pharma companies.

Company Highlights

Novel monoclonal antibodies to Nectin family of receptors and ligands are currently being generated and developed for solid and hematological malignancies. The company is seeking to establish a strategic partnership aimed to develop and commercialize some of the drug candidates. Prof. Mandelboim is a leading researcher in the field of immunology and cancer, focused on NK cells biology and function.

Key Shareholders

Integra Holdings, Yissum.

Funding

Extensive business development activity is ongoing, to support further development of the technology.

www.nectintx.com

More Companies